Delay of Events associated with ticagrelor use, as compared with clopidogrel, in the PLATO study
| Endpoint | Ticagrelor group n/total (%) | Clopidogrel group n/total (%) | HR*(95% CI)* | p Value | Delay of events† (days) (95% CI)† | Max observed percentile |
| 1) Death from vascular causes/MI‡ or stroke§ | 864/9333 (9.8) | 1014/9291 (11.7) | 0.84 (0.77 to 0.92) | <0.001 | 83 (37 to 128) | 10th |
| 2) MI | 504/9333 (5.8) | 593/9291 (6.9) | 0.84 (0.75 to 0.95) | 0.005 | 84 (31 to 136) | 5th |
| 3) Death from vascular causes, MI‡, stroke, severe recurrent ischaemia, recurrent ischaemia, TIA or other arterial thrombotic event¶ | 1290/9333 (14.6) | 1456/9291 (16.7) | 0.88 (0.81 to 0.95) | <0.001 | 98 (50 to 146) | 9th |
| 4) Death from any cause, MI‡ or stroke | 901/9333 (10.2) | 1065/9291 (12.3) | 0.84 (0.77 to 0.92) | <0.001 | 95 (49 to 139) | 9th |
| 5) Total major bleeding§§ | 961/9235 (11.6) | 929/9186 (11.2) | 1.04 (0.95 to 1.13) | 0.30 | −29 (−88 to 30) | 10th |
| 6) Non-CABG major bleeding. | 362/9235 (4.5) | 306/9186 (3.8) | 1.31 (1.08 to 1.60) | 0.006 | −95 (−17 to −19) | 5th |
*HRs from the original PLATO study are herein reported.
†DoEs were estimated by fitting Laplace regression models on the highest observed percentile.
‡MI was defined in accordance with the universal definition proposed in 2007.
§Composite endpoint of death from either vascular causes, MI or stroke.
¶Composite of first occurrence to either event.
§§Total major bleeding was defined as major life-threatening bleeding, fatal bleeding, intracranial bleeding, intrapericardial bleeding with cardiac tamponade, hypovolemic shock or severe hypotension due to bleeding and requiring pressors or surgery, a decline in the haemoglobin level of 5.0 g/L or more.
CABG, coronary-artery bypass grafting; MI, myocardial infarction; TIA, transient ischaemic attack.